Cardiogen Peptide: Studies and Status | Dose Track
App Library Tools Pricing Download
[Peptide · Compound guide]

Cardiogen: what it is, studies and status

Amounts studied · Approval status · Half-life notes

What is cardiogen?

Cardiogen is a short synthetic peptide (a tetrapeptide, four amino acids) studied mainly in St. Petersburg, Russia, as a "bioregulator" for heart tissue, alongside related peptides such as bronchogen and pancragen. It is not approved in the US, and we found no published study in people. It is not the same as CardioGen-82, an FDA-approved rubidium generator used for heart scans.

Also known as: cardiogen peptide.

Amounts studied

There is no approved product and no labeled strength we could confirm. The studies we found used rat tissue, cells and rats, so there is no amount studied in people.

Approval status and how it is used

Cardiogen is not an approved drug in the US. The only FDA-approved product with a similar name is CardioGen-82 (rubidium chloride Rb-82, made by Bracco), a different product given by injection for heart imaging.

All the studies we found are in cells and animals, and most come from St. Petersburg research groups. In heart tissue taken from young and old rats (Chalisova 2009), cardiogen increased cell growth and lowered a marker linked to cell death. In a comparison of four of these peptides on rat tissue (Zakutskiĭ 2006), each one increased growth in its matching tissue, cardiogen in heart tissue. In aging human prostate cells in a dish (Kheĭfets 2010), cardiogen raised several signaling proteins. In old rats with a transplanted tumor (Levdik 2009), cardiogen injections slowed tumor growth; the authors linked this to bleeding and cell death inside the tumor acting through its blood vessels.

Results in cells and rats often do not carry over to people.

Cardiogen half-life and time to peak

  • Half-lifeNot listed
  • Time to peak (Tmax)Not listed

We could not find a published human half-life for this compound. The studies we found were in cells and rats, so we do not list one.

How to track cardiogen in Dose Track

  1. Add cardiogen as a custom compound. Start typing its name and Dose Track fills in the details from its research library for you to check, and it sits next to everything else you take.
  2. Log each dose when you take it so your history shows exactly what you took and when.
  3. Set reminders on your own schedule, whether that is daily, weekly or every few days.
  4. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

How Dose Track handles peptides · Reconstitution calculator · Half-life calculator

ProstamaxLys-Glu-Asp-Pro BronchogenAla-Glu-Asp-Leu, AEDL peptide PancragenLys-Glu-Asp-Trp, KEDW peptide

Frequently asked questions

What is the half-life of cardiogen?+
We could not find a published human half-life for this compound. The studies we found were in cells and rats, so we do not list one.
Is cardiogen the same as CardioGen-82?+
No. CardioGen-82 is an FDA-approved rubidium Rb-82 generator made by Bracco and used for heart imaging. Cardiogen the peptide is an unapproved bioregulator from Russia with no published human studies we could find.
Can I track cardiogen in Dose Track?+
Yes. Cardiogen is in Dose Track's research library, so when you add it as a custom compound its details are filled in for you to check. You can then log each dose next to your other compounds, set reminders on your own schedule, and see your history next to your lab results. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

Sources

  1. Chalisova NI, et al. The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Adv Gerontol. 2009;22(3):409-413 (in Russian).
  2. Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Adv Gerontol. 2006;19:93-96 (in Russian).
  3. Kheĭfets OV, et al. Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging. Adv Gerontol. 2010;23(1):68-70 (in Russian).
  4. Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009;148(3):433-436.
  5. Drugs@FDA. CardioGen-82 (rubidium chloride Rb-82), NDA 019414, Bracco.

All compound guides · Reconstitution calculator · Supported medications